A collaboration between IIBR, Hadassa Medical Center and Tera Novel yielded a proprietary spray, containing minute quantities of an antibacterial and antiviral additive, developed in IIBR. Surgical masks sprayed externally were found to have strong and fast antibacterial activity for as long as 6 months (on-going). The additive toxicity was tested in a rigorous animal test, and a No Effect Dose was determined. The masks were labeled safe for skin irritation in yet another animal test. Moreover, the active mask does not emit any chemicals (gases or particles) to the wearer and conforms to the European standard for breathability. The active mask has been approved for use and is currently in mass production.
A unique collaboration between IIBR, the Weizmann Inst and IDEA Biomedical is set to develop a rapid detection of SARS-Cov-2 viruses in carriers’ clinical samples without compromising on sensitivity and accuracy. The technology is based on IDEA automatic microscopic platform the “HERMES” combined with the unique labeled antibodies developed at IIBR. Together we aim to achieve a rapid detection system, with a capacity of hundred samples per minutes. Such rapid and high throughput detection system will be crucial to enable economic and social life throughout the pandemic.
IIBR and Sirvir, a subsidiary company of Aposense, had recently started collaborative Research and Development Project with goal of accelerating development of a genetic therapy for the pandemic of Corona virus COVID-19.
The Israel Institute for Biological Research and the Weizmann Institute of Science will join efforts in advancing research designed to develop ways to combat the coronavirus. A Memorandum of Understanding (MoU) between the two Institutes on this matter has been signed in recent days.
The collaboration aims to assess the conditions for developing a project to isolate new neutralizing monoclonal antibodies directed at SARS-Cov-2.
Hundreds of volatile chemical compounds are exhaled in breath. In order to find markers specific for Corona, they need to be detected, identified and mapped. IIBR has developed unique methods for sensitive analysis and comprehensive data processing that are used in order to reliably identify these markers.
IIBR will explore the potential of Dyadic's industrially proven C1 gene expression platform to express gene sequences and targets developed by IIBR into both an rVaccine candidate and monoclonal antibodies (mAbs) that may help combat the outbreak of the COVID-19 virus (Coronavirus).